Journal of Diagnostics Concepts & Practice >

2021 , Vol. 20 >Issue 06: 533 - 539

DOI: https://doi.org/10.16150/j.1671-2870.2021.06.004

Original articles

The prognostic value of pretreatment 18F-FDG PET/CT in extranodal natural killer/T-cell lymphoma

Expand
  • 1a. Department of Nuclear Medicine; 1b. Collaborative Innovation Center for Molecular Imaging of Precision Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Ruijin Center, Shanghai 200025, China
    2a. Department of Radiology; 2b. Department of Bone and Tissue Tumor, Shanxi Provincial Cancer Hospital, Shanxi Taiyuan 030013, China

Received date: 2021-07-27

  Online published: 2021-12-25

Fold

Abstract

Objective: To assess use of pretreatment 18F-FDG PET/CT in prognosis prediction of extranodal natural killer/T-cell lymphoma(ENKTL). Methods: Sixty consecutive patients with newly diagnosed ENKTL underwent pretreatment 18F-FDG PET/CT were included and all patients received a pegaspargase-based regime. The maximum standardized uptake value (SUVmax), mean SUV (SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG) of the tumor, and clinical parameters including gender, age, ENKTL stage, nasal lymphoma infiltration range, extranasal lymphoma infiltration, lymph node involvement, bone marrow involvement. Survival curves and log-rank test were performed, and Cox proportional hazards model was used to assess the independent risk factors for overall survival(OS) and progression-free survival (PFS). Results: Survival analysis showed that MTV (P<0.001), TLG (P<0.001), PET/CT-based Ann Arbor stage (P<0.001), extranasal lymphoma infiltration (P=0.006), lymph node involvement (P=0.031), and bone marrow involvement on PET/CT (P<0.001) were predictive factors for 2-year OS, while SUVmax (P=0.653), SUVmean (P=0.446), and nasal lymphoma infiltration range (P=0.308) were not. SUVmax (P=0.274), SUVmean (P=0.213), nasal lymphoma infiltration range (P=0.621), and lymph node involvement (P=0.069) were not predictive factors for 2-year PFS,and MTV (P=0.001), TLG (P=0.009), PET/CT-based Ann Arbor stage(P<0.001), extranasal lymphoma infiltration (P<0.001), and bone marrow involvement on PET/CT (P<0.001) were predictive factors. Multivariate analysis showed PET/CT-based bone marrow involvement and Ann Arbor stage were independent prognostic factors for 2-year OS (P=0.046 and 0.019, respectively) and PFS (P=0.033 and 0.015), respectively. Conclusions: It reveals that 18F-FDG PET/CT-based bone marrow involvement and Ann Arbor stage are independent prognostic factors for both OS and PFS of newly diagnosed ENKTL.

Key words： extranodal natural killer/T-cell lymphoma; prognosis; 18F-FDG PET/CT

Cite this article

FENG Guowei, ZHANG Xiaojuan, GUO Rui, GUAN Zhe, WANG Yue . The prognostic value of pretreatment 18F-FDG PET/CT in extranodal natural killer/T-cell lymphoma[J]. Journal of Diagnostics Concepts & Practice, 2021 , 20(06) : 533 -539 . DOI: 10.16150/j.1671-2870.2021.06.004

References

[1] Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study[J]. J Clin Oncol, 2006, 24(4):612-618.
[2] Au WY, Ma SY, Chim CS, et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years[J]. Ann Oncol, 2005, 16(2):206-214.
[3] Li CC, Tien HF, Tang JL, et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma[J]. Cancer, 2004, 100(2):366-375.
[4] 姜璐, 赵维莅, 陈赛娟. 结外鼻型NK/T细胞淋巴瘤研究进展[J]. 诊断学理论与实践, 2012, 11(2):191-195.
[5] Foss FM, Zinzani PL, Vose JM, et al. Peripheral T-cell lymphoma[J]. Blood, 2011, 117(25):6756-6767.
[6] Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index[J]. Blood, 2004, 103(1):216-221.
[7] Kim SJ, Yoon DH, Jaccard A, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis[J]. Lancet Oncol, 2016, 17(3):389-400.
[8] Cheson BD. Role of functional imaging in the management of lymphoma[J]. J Clin Oncol, 2011, 29(14):1844-1854.
[9] 中华医学会核医学分会. 淋巴瘤18F-FDG PET/CT及PET/MR显像临床应用指南(2021版)[J]. 中核医学与分子影像杂志, 2021, 41(3):161-169.
[10] Chan WK, Au WY, Wong CY, et al. Metabolic activity measured by F-18 FDG PET in natural killer-cell lymphoma compared to aggressive B- and T-cell lymphomas[J]. Clin Nucl Med, 2010, 35(8):571-575.
[11] Khong PL, Pang CB, Liang R, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies[J]. Ann Hematol, 2008, 87(8):613-621.
[12] Moon SH, Cho SK, Kim WS, et al. The role of 18F-FDG PET/CT for initial staging of nasal type natural killer/T-cell lymphoma: a comparison with conventional staging methods[J]. J NuclMed, 2013, 54(7):1039-1044.
[13] Zhou X, Lu K, Geng L, et al. Utility of PET/CT in the diagnosis and staging of extranodal natural killer/T-cell lymphoma: a systematic review and meta-analysis[J]. Medicine (Baltimore), 2014, 93(28):e258.
[14] Fujiwara H, Maeda Y, Nawa Y, et al. The utility of positron emission tomography/computed tomography in the staging of extranodal natural killer/T-cell lymphoma[J]. Eur J Haematol, 2011, 87(2):123-129.
[15] Wu HB, Wang QS, Wang MF, et al. Utility of 18F-FDG PET/CT for staging NK/T-cell lymphomas[J]. Nucl Med Commun, 2010, 31(3):195-200.
[16] Karantanis D, Subramaniam RM, Peller PJ, et al. The value of [(18)F] fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma[J]. Clin Lymphoma Myeloma, 2008, 8(2):94-99.
[17] Suh C, Kang YK, Roh JL, et al. Prognostic value of tumor 18F-FDG uptake in patients with untreated extranodal natural killer/T-cell lymphomas of the head and neck[J]. J Nucl Med, 2008, 49(11):1783-1789.
[18] 沈文斌, 郭睿, 李彪. 18F-FDG PET/CT代谢参数在NK/T细胞淋巴瘤预后价值的评估[J]. 诊断学理论与实践, 2019, 18(3):349-352.
[19] Kim SJ, Kim WS. Treatment of localized extranodal NK/T cell lymphoma, nasal type[J]. Int J Hematol, 2010, 92(5):690-696.
[20] Ding H, Chang J, Liu LG, et al. High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed/refractory extranodal natural killer/T cell lymphoma: a retrospective study[J]. Int J Hematol, 2015, 102(2):181-187.
[21] Liang R, Gao GX, Chen JP, et al. A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial in Northwest China[J]. Hematol Oncol, 2017, 35(4):619-629.
[22] Sabattini E, Bacci F, Sagramoso C, et al. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview[J]. Pathologica, 2010, 102(3):83-87.
[23] Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin′s Disease Staging Classification[J]. Cancer Res, 1971, 31(11):1860-1861.
[24] Xu PP, Xiong J, Cheng S, et al. A phase Ⅱ study of methotrexate, etoposide, dexamethasone and pegaspargase sandwiched with radiotherapy in the treatment of newly diagnosed, stage IE to IIE extranodal natural-Killer/T-cell lymphoma, nasal-type[J]. EBioMedicine, 2017, 25:41-49.
[25] Schöder H, Noy A, Gönen M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin′s lymphoma[J]. J Clin Oncol, 2005, 23(21):4643-4651.
[26] Jiang C, Zhang X, Jiang M, et al. Assessment of the prognostic capacity of pretreatment, interim, and post-therapy (18)F-FDG PET/CT in extranodal natural killer/T-cell lymphoma, nasal type[J]. Ann Nucl Med, 2015, 29(5):442-451.
[27] Bai B, Huang HQ, Cai QC, et al. Predictive value of pretreatment positron emission tomography/computed tomography in patients with newly diagnosed extranodal natural killer/T-cell lymphoma[J]. Med Oncol, 2013, 30(1):339.
[28] 张亚飞, 王珍, 林丽莉, 等. 治疗前18F-FDG PET/CT SUVmax对Ⅰ~Ⅱ期鼻型NK/T细胞淋巴瘤的预后判断价值[J]. 中华核医学与分子影像杂志, 2018, 38(9):602-604.
[29] Khong PL, Huang B, Lee EY, et al. Midtreatment 18F-FDG PET/CT scan for early response assessment of SMILE therapy in natural killer/T-cell lymphoma: a prospective study from a single center[J]. J Nucl Med, 2014, 55(6):911-916.
[30] Xie M, Zhai W, Cheng S, et al. Predictive value of F-18 FDG PET/CT quantization parameters for progression-free survival in patients with diffuse large B-cell lymphoma[J]. Hematology, 2016, 21(2):99-105.
[31] Chang Y, Fu X, Sun Z, et al. Utility of baseline, interim and end-of-treatment(18)F-FDG PET/CT in extranodal natural killer/T-cell lymphoma patients treated with L-asparaginase/pegaspargase[J]. Sci Rep, 2017, 7:41057.
[32] Li T, Zhang B, Ye Y, et al. Immunohistochemical and genetic analysis of Chinese nasal natural killer/T-cell lymphomas[J]. Hum Pathol, 2006, 37(1):54-60.
[33] Kwong YL, Chan AC, Liang RH. Natural killer cell lymphoma/leukemia: pathology and treatment[J]. Hematol Oncol, 1997, 15(2):71-79.
[34] Su YJ, Wang PN, Chang H, et al. Extranodal NK/T-cell lymphoma, nasal type: clinical features, outcome, and prognostic factors in 101 cases[J]. Eur J Haematol, 2018, 101(3):379-388.
[35] Xu PP, Wang Y, Shen Y, et al. Prognostic factors of Chinese patients with T/NK-cell lymphoma: a single institution study of 170 patients[J]. Med Oncol, 2012, 29(3):2176-2182.
Options
Outlines

/

〈 〉